Continued treatment with IMVT-1402 for adults with Graves' disease
Tests IMVT-1402 over a longer time in adults with Graves' disease.
Key facts
- Who runs it
- Immunovant Sciences GmbH
- Where
- Daegu and Gyeonggi-do, South KoreaSee the 3 sitesAlso in 10 other countries, 128 sites
- Trial code
- Registry title
- A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
- Status
- Enrolling by invitation
- Phase
- Phase 2
- People taking part
- 372 people, planned
- Started
- 26 Jan 2026
- Expected to end
- Mar 2030
- Type of study
- Interventional, 3 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- IMVT-1402
- Record updated
- 29 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Graves' disease who completed one of two earlier IMVT-1402 studies. People are placed in 1 of 3 groups based on their disease status at the end of that study.
- Age
- 18 Years and older
- Sex
- All sexes can join
- Disease stage
- Graves' disease, an overactive thyroid caused by the immune system
- Earlier treatment
- Must have completed Study IMVT-1402-2502 (NCT06727604) or Study IMVT-1402-2503 (NCT07018323).
Main reasons for not taking part
- Permanently stopped the study drug during the treatment period of the earlier study
- Met the study stopping rules at any point in the earlier study
- Other, more specific criteria are set in the protocol
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503
- Other, more specific inclusion criteria are defined in the protocol
Who cannot take part
- Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study
Where in South Korea
Also in 10 other countries, 128 sites
- DaeguHospital not named in the registryEnrolling by invitation
- Gyeonggi-doHospital not named in the registryEnrolling by invitation
- Gyeonggi-doHospital not named in the registryEnrolling by invitation
About the trial
What the trial wants to find out
This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.
The 3 groups in the trial
- Group ATreatment being tested
Treatment: IMVT-1402
- Group BNo study treatment, for comparison
- Group CNo study treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
- Plain-language title
- Continued treatment with IMVT-1402 for adults with Graves' diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 29 September 2026